Vir

Vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. Vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. The company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.

Lead investors include ARCH Venture Partners and the Bill & Melinda Gates Foundation, and will be joined by others including sovereign wealth funds, public mutual funds and prominent individuals and family offices.

Vir Biotechnology is investing in cures, treatments, and preventions for challenging viral and bacterial diseases, including those caused by drug-resistant bacteria and emerging pathogens.

Company Details

Expertise:

Categories:

Website:

Vir